Mutagen sensitivity and risk of second cancer in younger adults with head and neck squamous cell cancer: 15-year results

B. Bukovszky1,2,3 · J. Fodor3 · G. Székely3 · S. Zs. Kocsis3 · F. Oberna3 · T. Major1,3 · Z. Takácsi-Nagy1,3 · C. Polgár1,3 · Z. Jurányi3

Received: 18 November 2021 / Accepted: 22 February 2022 / Published online: 31 March 2022
© The Author(s) 2022

Abstract
Purpose To evaluate the mutagen sensitivity phenotype on the risk of second primary cancer (SPC) in patients with head and neck squamous cell carcinoma (HNSCC), and to estimate the long-term rate of SPC and the outcome with SPC.
Methods A survey was made regarding SPC among 124 younger (≤ 50 years) adults with HNSCC who were enrolled in a pretreatment mutagen sensitivity investigation during 1996–2006. Mutagen sensitivity was assessed by exposing lymphocytes to bleomycin in vitro and quantifying the bleomycin-induced chromatid breaks per cell (b/c). Patients were classified as hypersensitive (> 1 b/c) or not hypersensitive (≤ 1 b/c).
Results Mean follow-up time for all patients was 68 months (range: 5–288 months), and the 15-year cancer-specific survival was 15%. Twenty patients (16%) developed a SPC (15-year estimated rate: 41%), and half of them was hypersensitive. The crude rate of SPC for hypersensitive (n = 65) or not hypersensitive (n = 59) patients were 15 and 17%, respectively (p = 0.4272). The 15-year estimated rate of SPC for hypersensitive and not hypersensitive patients was 36 and 48%, respectively (p = 0.3743). Gender, UICC stages, anatomical sites of index cancer did not prove to be a significant risk factor for SPC. Forty-five percent of SPC developed after the 10-year follow-up. The 3-year cancer-specific survival was 23% with SPC.
Conclusion According to our findings, mutagen hypersensitivity was not associated with an increased SPC risk in HNSCC patients. Patients are at a lifelong risk of developing a SPC. Survival with SPC is very poor.

Keywords Head and neck squamous cell cancer · Risk of second primary cancer · Survival with second primary cancer · Mutagen sensitivity · Bleomycin test

Introduction
Smoking and excessive alcohol consumption are the main causal factors associated with HNSCC (head and neck squamous cell carcinoma). However, only a small proportion of smokers and drinkers (about 10%) develop HNSCC, suggesting that variations in genetic susceptibility may play an important role in the etiology of cancer [1, 2]. In 1983, the bleomycin assay was suggested by Hsu [3] as a biological marker for the development of environmentally induced cancer. The method is based on the scoring of bleomycin (BLM)-induced chromatid breaks occurring in cultured lymphocytes in vitro in the late G2 phase of the cell cycle. Spitz et al. [4] used this method to investigate the association between mutagen-induced chromosome damage and cancer risk and the interaction of carcinogenic exposures and chromosome damage in healthy and untreated patients with upper aerodigestive tract cancer. The cancer patients showed increased chromosome sensitivity (65.2% of cancer patients had >0.8 b/c [breaks/cell]) compared to only 23.6% of the control patients had it, and chromosome sensitivity remained a strong and significant risk factor for head and neck cancer after adjustment for potential confounding from age, sex, cigarette smoking, and alcohol con-
They concluded that the thesis that chromosome instability and/or defective DNA repair may underlie susceptibility to environmental carcinogenesis is plausible and may present a promising avenue for further research. Individuals with genetic instability may generate more cells with mutations or chromosomal aberrations than those with more stable genomes [5].

Young patients with HNSCC can be treated successfully with surgery and radiotherapy (RT), but they often develop second primary cancer (SPC). The leading cause of morbidity and mortality in these patients is the development of SPC [6]. Impact of smoking status, alcohol consumption, index tumor site, and disease stage on SPC development in patients with cancer of the oral cavity, pharynx, and larynx have been reported previously [7–9]. However, these factors do not account for the development of all SPCs. It is likely that genetic susceptibility also contributes to the development of SPC [10, 11]. Several studies have indicated that mutagen sensitivity may be a valuable biomarker of susceptibility to the development of multiple primary tumors [12–14].

The aim of this study was to determine the predictive value of mutagen sensitivity for the development of SPC in a group of HNSCC patients who were tested for mutagen sensitivity and treated between 1996 and 2006 at the National Institute of Budapest, Hungary [15, 16]. Another aim was to estimate the rate of SPC and the outcome with SPC.

Materials and methods

Between 1996 and 2006, 432 patients with HNSCC underwent mutagen sensitivity assay before treatment. Informed consent was obtained from each study subject before enrollment and study protocol was approved by the institutional review board. The aim of that test was to clarify the usefulness of the bleomycin sensitivity assay elaborated in the USA as a biomarker of HNSCC, to explain the association between HNSCC susceptibility and exposure to carcinogens. The results were published elsewhere [15, 16]. From these patients, 124 met the following conditions: drinker and smoker, age ≤ 50 years at the time of bleomycin test, human papillomavirus (HPV)-negative oral cavity, pharyngeal (except nasopharyngeal) or laryngeal squamous cell cancer, treatment and follow-up were performed at our institute. We reviewed records of patients and compared pretreatment mutagen sensitivity between patients with or without SPC. SPC was partly defined according to the criteria of second primary tumor prevention trial of the M.D. Anderson Cancer Center [11]: the SPC must be diagnosed as malignant, has to be at least 2 cm from site of the index tumor, and has to occur ≥ 4 months after the diagnoses of the index tumor. Mutagen sensitivity was measured in vitro in lymphocytes by counting chromatid breaks induced by bleomycin as described previously [15, 16]. Briefly, blood cultures were incubated for 3 days and then exposed to bleomycin (30 µg/ml) for 5 h. Cells were harvested, and chromatid breaks were scored in 100 metaphases per sample, and recorded as the mean number of breaks per cell (b/c). The patient was classified hypersensitive if the mean number of b/c was > 1. The following survival endpoints were used: any death for overall survival, death from head and neck cancer for cancer-specific survival, death from SPC for survival with SPC, the appearance of SPC for SPC-free survival (time to SPC). Intervals to endpoints were examined with Kaplan–Meier model [17], and the curves were compared with log-rank test. The effect of the possible prognostic factors on the probability of the incidence of a SPC were examined in Cox regression model [18]. Statistical differences in proportions and means were assessed by 2-sample t-test and by Fisher exact test. GraphPad Prism (version 5.01 for Windows, GraphPad Software, San Diego, CA, USA) and Statistica (version 13.5.0.17, TIBCO Software Inc., Palo Alto, CA, USA) program packages were used for data analysis. A p value ≤ 0.05 was considered statistically significant.

Results

Cytogenetic and clinical characteristics of the patients are given in Table 1. Of the four anatomical sites, tumors of oral cavity (34%) represented the largest group. The rate of patients with stage IV disease was high (43%), and few patients (n = 12) were treated with chemotherapy alone. Most patients were subjected to surgery and adjuvant RT. Therapy is detailed as follows: 86 patients were subjected to surgery. The number of R0 or R1 resection was 61 and 25, respectively. Of the 86 patients, 84 underwent lymphadenectomy: 20 were node negative and 64 were node positive. Extracapsular tumor extension (ECE) was seen in 14 node-positive patients. Response rate (complete or partial response) for radiochemotherapy alone, definitive RT or chemotherapy alone, was 9/10, 6/7 and 7/12.

Mean follow-up time for all patients and alive patients was 68 months (range: 5–288 months) and 222 months (range: 184–249 months), respectively. Nine patients are still alive, and 115 have died. Crude overall survival rate is 7%. Ten patients died of internal disease. The crude rate of cancer-specific survival is 15%. The estimated rate of 15-year overall or cancer-specific survival is 14.5 and 19%, respectively.

Out of 124 patients, 20 (16.1%) developed SPC. The characteristics of the 20 patients are given in Table 2. The majority (n = 13; 65%) of SPC were HNSCC. Seven of them developed outside of head and neck region (esophag-
Table 1 Clinical and cytogenetic characteristics

| Characteristics          | Patients, n (%) |
|--------------------------|-----------------|
| **Mean age**             | 45.8 years (range: 23–50 years) 124 (100) |
| **Mutagen sensitivity**  |                 |
| Hypersensitive (> 1 b/c) | 65 (52)         |
| No hypersensitive (≤ 1 b/c) | 59 (48)       |
| **Anatomical subsite**   |                 |
| Oral cavity              | 48 (38)         |
| Oropharynx               | 27 (22)         |
| Hypopharynx              | 32 (26)         |
| Larynx                   | 17 (14)         |
| **Gender**               |                 |
| Male                     | 107 (86)        |
| Female                   | 17 (14)         |
| **UICC stage**<sup>a</sup> |             |
| I                        | 3 (2)           |
| II                       | 20 (16)         |
| III                      | 48 (39)         |
| IV                       | 53 (43)         |
| **Treatment**<sup>b</sup> |               |
| Surgery alone            | 9 (7)           |
| Radiotherapy alone       | 7 (6)           |
| Surgery + adjuvant radiotherapy | 71 (57) |
| Surgery + radiochemotherapy | 6 (5)        |
| Radiochemotherapy        | 10 (8)          |
| Chemotherapy alone       | 12 (10)         |
| Palliative therapy       | 9 (7)           |

<sup>a</sup>UICC Union Internationale contre de cancer, TNM Classification of Malignant Tumours—7th edition  
<sup>b</sup>Treatments are detailed in the text

The mean time to SPC was 118 months (range: 4–272 months). The 10-, 15-, or 20-year estimated rate of SPC was 24, 41 and 65%, respectively. In 3 patients, the index cancer and the SPC occurred in the same subregion (oral cavity, contralateral edge of the tongue). In these 3 cases the time to SPC was 161, 99 and 152 months (more than 5 years), and in every case the distance between the index cancer and SPC was greater than 2 cm. None of the patients with SPC had persistent disease or percontinuitatem invasion associated with SPC. The therapy of index cancer for patients with SPC was as follows: surgery alone (n = 2, R0 resection), surgery and adjuvant RT (n = 17, R0 or R1 resection 16 and 1), surgery and adjuvant radiochemotherapy (n = 1, with R1 resection and extracapsular tumor extension).

The number of hypersensitive (>1 b/c) patients were 65 (mean b/c: 1.43±0.39). Ten of them (15%) developed SPC. In the not hypersensitive group (n = 59, mean b/c: 0.74±0.18), 10 patients (17%) also developed SPC (p = 0.4272). The mean value of b/c for patients with SPC and without SPC was 1.02±0.37 (range: 0.52–1.6) and 1.12±0.48 (range: 0.35–2.8; p = 0.4062). The mean value of b/c was separately evaluated for patients with ≥36 months to SPC development. The mean b/c value of patient with “late” (≥36 months) SPC (n = 16) or patients without SPC (n = 104) was 1.02 (range: 0.52–1.60) and 1.12 (range: 0.35–2.80), respectively (p = 0.5724). The 15-year estimated rate of overall survival for hypersensitive or not hypersensitive patients was 16.9 and 11.0%, respectively (p = 0.4164). The second cancer-free survival curves by mutagen sensitivity are shown in Fig. 1. The 15-year estimated rate of second primary cancer for not hypersensitive or hypersensitive patients was 48 and 36%, respectively (p = 0.3743). The median and mean survival time with SPC was 23 months (range: 8–82 months) and 15 months. The 2- and 3-year cancer-specific survival with SPC was 38 and 23%, respectively (Fig. 2). The 45% of SPC was developed after 10 years (between 152 and 272 months). The crude
### Table 2  Characteristics of the 20 primary cancer patients

| Gender | Index cancer | b/c | UICC stage | Site of SPC | UICC stage | Time to SPC (months) | Histology | Survival with SPC (months) |
|--------|--------------|-----|------------|-------------|------------|----------------------|-----------|--------------------------|
| 1      | Male         | Oral cavity | 0.83 | II         | Oropharynx | II                   | 109       | SCC                      | 31        |
| 2      | Male         | Oral cavity | 0.97 | I          | Oral cavity | III                  | 161       | SCC                      | 15        |
| 3      | Male         | Oral cavity | 1.58 | II         | Esophagus  | III                  | 165       | SCC                      | 15        |
| 4      | Male         | Oral cavity | 1.27 | II         | Oral cavity | III                  | 99        | SCC                      | 82        |
| 5      | Male         | Hypopharynx | 1.02 | III        | Oral cavity | III                  | 24        | SCC                      | 30        |
| 6      | Male         | Hypopharynx | 0.59 | III        | Lung       | III                  | 36        | SCC                      | 14        |
| 7      | Male         | Hypopharynx | 1.51 | III        | Esophagus  | III                  | 24        | SCC                      | 10        |
| 8      | Male         | Larynx      | 0.55 | II         | Oropharynx | IV                   | 208       | SCC                      | 10        |
| 9      | Male         | Larynx      | 0.64 | II         | Oropharynx | III                  | 84        | SCC                      | 12        |
| 10     | Male         | Larynx      | 0.52 | III        | Oropharynx | IV                   | 170       | SCC                      | 13        |
| 11     | Male         | Larynx      | 0.87 | III        | Oral cavity | IV                  | 236       | SCC                      | 8         |
| 12     | Male         | Oral cavity | 0.88 | II         | Lung       | III                  | 100       | SCC                      | 11        |
| 13     | Male         | Oral cavity | 0.72 | III        | Esophagus  | III                  | 73        | SCC                      | 8         |
| 14     | Male         | Larynx      | 0.78 | III        | Lung       | III                  | 15        | SCLC                     | 12        |
| 15     | Male         | Oral cavity | 1.52 | II         | Oral cavity | III                  | 152       | SCC                      | 48        |
| 16     | Male         | Oropharynx  | 1.14 | III        | Oral cavity | III                  | 4         | SCC                      | 81        |
| 17     | Female       | Larynx      | 1.34 | III        | Oropharynx | III                  | 156       | SCC                      | 16        |
| 18     | Female       | Oral cavity | 1.60 | II         | Larynx     | III                  | 74        | SCC                      | 12        |
| 19     | Female       | Hypopharynx | 1.05 | III        | Oropharynx | II                   | 235       | SCC                      | 10        |
| 20     | Male         | Oropharynx  | 1.45 | II         | Prostate   | III                  | 272       | AC                       | 16a       |
| Mean   | –            | –            | –    | –          | –          | 1.02 ± 0.42           | 118       | –                        | 22        |

**b/c chromatid breaks/cell, UICC Union Internationale contre de cancer, TNM Classification of Malignant Tumours 7th edition, SPC Second primary cancer, SCC squamous cell cancer, SCLC small cell lung cancer, AC adenocarcinoma**

a19 patients died of cancer and 1 died of coronary disease

### Table 3  Second primary cancer rate by index cancer site

| Index cancer | Patients, n (%) | b/c, mean ± SD | Mean FUP time (range) | Crude rate, % (n) |
|--------------|-----------------|----------------|-----------------------|-------------------|
| Oral cavity  | 48 (38)         | 1.18 ± 0.51    | 70 (5–240)            | 13 (6)            |
| Oropharynx   | 27 (22)         | 1.10 ± 0.42    | 75 (6–288)            | 15 (4)            |
| Hypopharynx  | 32 (26)         | 1.10 ± 0.50    | 49 (6–244)            | 13 (4)            |
| Larynx       | 17 (14)         | 0.90 ± 0.28    | 84 (7–244)            | 35 (6)            |
| All          | 124 (100)       | 1.10 ± 0.47    | 68 (5–288)            | 16 (20)           |

**b/c chromatid-break/cell, SD standard deviation**

*FUP time follow-up time; Oral cavity + Oropharynx vs. Hypopharynx + Larynx p = 0.6253*

### Table 4  Second primary cancer rate by UICC stage

| Stage | Patients, n (%) | b/c, mean ± SD | Mean FUP time (range) | Crude rate, % (n) |
|-------|-----------------|----------------|-----------------------|-------------------|
| I     | 3 (2)           | 1.09 ± 0.42    | 216 (176–240)         | 33 (1)            |
| II    | 20 (16)         | 1.20 ± 0.40    | 145 (21–288)          | 45 (9)            |
| III   | 48 (39)         | 1.01 ± 0.48    | 82 (11–249)           | 21 (10)           |
| IV    | 53 (43)         | 1.15 ± 0.47    | 17 (5–77)             | 0 (0)             |
| All   | 124 (100)       | 1.10 ± 0.47    | 68 (5–288)            | 16 (20)           |

**b/c chromatid breaks/cell, SD standard deviation, Stage TNM Classification of Malignant Tumours 7th edition**

*FUP time follow-up time; stage I–II vs. stage III–IV p = 0.0009*
Table 5 The 15-year estimated rate of second primary cancer by variables (univariate analysis)

| Variables                        | %   | p-value  | RR (95% CI)         |
|----------------------------------|-----|---------|---------------------|
| Gender                           |     | 0.5071  |                     |
| Male                             | 46  | –       | 1.00                |
| Female                           | 24  | –       | 0.6698 (0.2277–1.970) |
| Site of index cancer             |     | 0.1049  |                     |
| Oral cavity + oropharynx         | 39.5| –       | 1.00                |
| Hypopharynx + larynx             | 44.1| –       | 2.009 (0.7924–5.084) |
| UICC stage                       |     | 0.9615  |                     |
| Early (I + II)                   | 46.4| –       | 1.00                |
| Locally advanced (III–IV)        | 31.9| –       | 0.9797 (0.4078–2.354) |
| Mutagen sensitivity              |     | 0.3072  |                     |
| Not hypersensitive               | 47.6| –       | 1.00                |
| Hypersensitive                   | 36.1| –       | 0.6463 (0.2634–1.586) |
| Radiotherapy                     |     | 0.8767  |                     |
| No                               | 28  | –       | 1.00                |
| Yes                              | 43  | –       | 1.120 (0.2427–5.172) |

RR relative risk, CI confidence interval, UICC stage TNM Classification of Malignant Tumours 7th edition

Discussion

Several studies reported that bleomycin-induced mutagen sensitivity, reflecting latent genetic instability, is a significant predictor of SPC. HNSCC patients with SPC have higher b/c scores than SPC-free individuals [12–14, 19–21]. Schantz et al. [12] from the M. D. Anderson Cancer Center (Houston) used the bleomycin test first to estimate the risk of SPC in patients with HNSCC. The rate of SPC was significantly higher in the hypersensitive (b/c > 1) than in the not hypersensitive group (33% vs. 8%), and hypersensitivity increased the risk by 4.4 times. A weakness of their study was the short follow-up time: median < 2 years (range, 4–31 months). They extended the study to include 278 patients, and the results were published in 1994. Mutagen hypersensitivity (b/c > 1) also increased the risk of developing SPC. The mean b/c value for patients with SPC was 1.17 (±0.54) compared with 0.98 (±0.44) for SPC-free patients (p = 0.044). The follow-up time was again very short. The mean time from the diagnosis to the development of the SPC was only 10.5 months [13]. The mean time to SPC for our patients was more than 10 times longer (118 months). Cloos et al. [19] examined the mutagen sensitivity as a biomarker of SPC in Dutch HNSCC patients (n = 218). Nineteen of them (8.7%) developed SPC. The follow-up time was relatively short (median: 4.5 years). In this prospective study there was no difference between the groups (with or without SPC) with respect to mutagen sensitivity. They also found that patients who developed SPC ≥ 3 years after the index cancer had a significantly higher mean b/c value compared to patients with early SPC. In our study, the mean b/c value of patient with “late” (≥ 36 months) SPC (n = 16) or without SPC (n = 104) was not significantly different. Minard et al., from the M. D. Anderson Cancer Center studied the risk of SPC in patients with early stage HNSCC, who were enrolled in a placebo-controlled chemoprevention trial of low-dose 13-cis-retinoic acid to reduce the occurrence of SPC. Of the 1080 participants, a sample of 303 Caucasian patients was potentially available for their analysis. Overall, 50 of 303 patients (16.5%) developed SPC. Data on average follow-up time were not provided. The bleomycin-induced chromatid breaks were not associated with an increased risk. The lack of association between mutagen hypersensitivity and SPC was partly attributed to early UICC stage (I–II).
of the enrolled patients [20]. A half year later, they published their experience with 991 patients. The mean follow-up time for living patients was 7 years, and the b/c cutoff value for mutagen sensitivity was 0.50. Among patients with SPC, the hypersensitive (b/c ≥ 0.5) and not hypersensitive (b/c < 0.5) rate was 82% (n = 243) and 18% (n = 55), respectively, p = 0.036 [21].

Our patients with HNSCC before treatment underwent bleomycin sensitivity assay and the method was not suitable for the assessment of individual index cancer risk due to overlapping of b/c values with those of controls [15, 16]. Here, we present our experience with the association between SPC and mutagen sensitivity in younger adults with HNSCC with the longest published follow-up time: mean time for all patients and alive patients was 5.8 and 18.5 years, respectively. The long follow-up time has to be emphasized, as patients are at high risk of developing SPC even 10 years after initial treatment. In our series, 45% of SPC developed after 10 years. In the current analysis, mutagen hypersensitivity was not significantly associated with an increased risk of developing SPC. The 15-year estimated rate of SPC for hypersensitive (b/c > 1.0) and not hypersensitive (b/c ≤ 1.0) patients was 36 and 48%, respectively. Cloos et al. [14] found significantly higher break/cell values in patients with multiple cancer (mean, 1.2), than in patients with a single cancer (mean, 0.96; p = 0.025). Our comparable values were 1.02 and 1.10 (p = 0.4062), respectively. The investigators from the M. D. Anderson Cancer Center changed the experimental parameters several times. First, the cutoff value for b/c was 1.0, and later it was decreased to 0.5. Furthermore, in their large-scale study, the SPC was counted together with local relapse [21]. In our series, the number of patients with b/c ≤ 0.5 was only nine and local relapse was not included in the analysis. Metastasis or local relapse was not considered as SPC.

Several studies investigated the risk of SPC and its impact on survival independently of mutagen sensitivity, and published long-term (more than 10-year) results [22–24]. In a large multicentric study (99,257 patients), the 20-year cumulative rate of SPC was 36%, and smoking and alcohol drinking increased the risk of developing SPC. Increased risks of SPCs persisted 10 years after diagnosis of the first primary [22]. Our patients also had a lifelong risk of developing SPC. All of our patients were drinkers and smokers, and the majority of them did not stop smoking and drinking. Otolaryngologists from Oslo studied 2063 head and neck patients [23]. The crude rate of SPC was 17%. The mean time to SPC was more than 4 years, and the median survival time with SPC was 12 months. SPC was most common in patients with limited (stage I/II) disease. Patients with a poor prognosis did not live long enough to develop SPC. In our series, none of the patients with stage IV disease developed SPC, and the crude rate of SPC was 16%, close to their rate. The survival with SPC was also very poor. The median and mean survival time was 23 and 15 months, respectively. In the study of Tiwana et al. from British Columbia, Canada [24], the follow-up time was 25 years (median time for alive patients: 23.2 years), and the crude incidence of SPC was 27%. Oral cavity and oropharyngeal index cancer were more likely to develop SPC. The estimated 5-year overall survival with SPC was 15%. According to our analysis the anatomical subsite had no significant impact on the risk of SPC. In a German observation study [25], 118 patients (close to our sample) with HNSCC were selected in a SPC survey. The crude rate of SPC was 18%. Interestingly, 52% of SPC were diagnosed within 2 years. At our patients, only 2 SPCs were diagnosed within 2 years (4 and 15 months). Bugter et al. [26] from the Erasmus Cancer Institute, Rotterdam studied the risk factor of SPC in a Cox model. The crude rate of SPC was 15.6%. Smoking and alcohol consumption, comorbidity, and the oral cavity subsite were risk factors for SPCs. All of our patients were drinkers and smokers; therefore, we did not investigate these potential risk factors. In a current, population-based study from the United States, the smoking-related cancers were studied. Among 10 smoking-related cancer sites head and neck cancer patients had the highest risk of developing a SPC [27].

We studied the following risk factors of SPC in a Cox model: gender, ULCC stage, site of index cancer, RT and mutagen sensitivity (all of our patients were smokers and drinkers). None of them proved to be a significant predictor of SPC development. Arie et al. [28] from Israel assessed the incidence of SPCs in patients with head and neck malignancies, according to treatment modality. Neither RT nor chemotherapy was associated with SPC development. Patients with an advanced-stage cancer had less time to develop SPC compared to early stage patients. Lifelong follow-up has to be emphasized because of permanent risk of SPC. Boakye et al. [29] examined the incidence and sites of SPCs stratified by a first HPV-associated HNSCC compared with non-HPV-associated HNSCC. Incidence of SPCs was higher among those with non-HPV-associated HNSCC than from potentially HPV-associated HNSCC. Among 109,512 patients with first HNSCC, 13,517 (12.3%) developed SPC (9.6% for patients diagnosed with a first potentially HPV-associated HNSCC and 14.0% for patients with a first non-HPV-associated HNSCC). All of our patients had HPV-negative cancer.

Chemoprevention of SPC in HNSCC patients are discussed in several publications [4, 5, 12, 19, 21]. In a large multicentric trial from the United States, the conclusion was that further prevention trials are needed to find an appropriate compound. In this trial, the low-dose 13-isoretinoic acid for 2 years did not decrease the incidence of SPC. Mutagen sensitivity as a biomarker was not involved in this study to define patients with high risk of SPC development.
Conclusion

HNSCC survivors had an increased lifelong risk of developing SPC. The risk of developing SPC was higher in patients with less advanced cancer. Its incidence rate is high even after the 10-year follow-up. Survival is poor with SPC. Our results show that mutagen hypersensitivity does not increase the risk of SPC development. Therefore, mutagen sensitivity cannot be used as a biomarker to predict which patients will develop SPC.

Funding This work was supported by the National Laboratories Excellence program (under the National Tumor Biology Laboratory project (NLF-17)) and the Hungarian Thematic Excellence Program (TKP2021-EGA-44).

Funding Open access funding provided by National Institute of Oncology.

Declarations

Conflict of interest B. Bukovszky, J. Fodor, G. Székely, S.Z. Kocsis, F. Oberna, T. Major, Z. Takácsi-Nagy, C. Polgár and Z. Jurányi declare that they have no competing interests.

Ethical standards For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Li FP, Montesano R (1994) Interactions of cancer susceptibility genes and environmental carcinogens. American Association for Cancer Research (AACR), International Agency for Research on Cancer (IARC) joint conference. Cancer Res 54:4243–4247
2. Hsu TC, Spitz MR, Schantz SP (1991) Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers 1:83–89
3. Hsu TC (1983) Genetic instability in the human population: a working hypothesis. Hereditas 98:1–9
4. Spitz MR, Fueger JJ, Beddingfield NA, Annegers JF, Hsu TC, Newell GR, Schantz SP (1989) Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 49:4626–4628
5. Spitz MR, Wu X, Jiang H, Hsu TC (1996) Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl 25S:80–84
6. Lippman SM, Hong WK (1989) Second malignant tumors in head and neck squamous-cell carcinoma—the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17:691–694
7. Schottenfeld D, Gann RC, Wynder EL (1974) The role of alcohol and tobacco in multiple primary cancers of the upper digestive system, larynx, and lung: a prospective study. Prev Med 3:277–293
8. Silverman S, Gorsky M, Greenspan D (1983) Tobacco usage in patients with head and neck carcinomas: a follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 106:33–35
9. Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS et al (1994) Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 86:131–137
10. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, Lippman SM et al (2001) The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck region chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10:823–829
11. Do KA, Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK et al (2004) Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 101:2837–2842
12. Schantz SP, Spitz MR, Hsu TC (1990) Mutagen sensitivity in patients with head and neck cancers: a biological marker for risk of multiple primary malignancies. J Natl Cancer Inst 82:1773–1775
13. Spitz MR, Hoque A, Trizna Z, Schantz SP, Amos CI, King TM et al (1994) Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 86:1681–1684
14. Cloos J, Braakhuis BJM, Steen I, Copper MP, de Vries N, Nauta JJP, Snow GB (1994) Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56:816–819
15. Székely G, Reménar É, Kásler M, Gundy S (2003) Does the bleomycin sensitivity assay express cancer phenotype? Mutagenesis 18:59–63
16. Székely G, Reménar É, Kásler M, Gundy S (2005) Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis 20:381–385
17. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457–481
18. Cox DR (1972) Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34:187–220
19. Cloos J, Leemans CR, van der Sterre ML, Kuik DJ, Snow GB, Braakhuis BJ (2000) Mutagen sensitivity as a biomarker for sec-
ond primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 9:713–717
20. Minard CG, Spitz MR, Wu X, Hong WK, Etzel CJ (2006) Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer 106:2636–2644
21. Wu X, Gu J, Dong Q, Do KA, Hong WK, Spitz MR et al (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194–7201
22. Chuang SC, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Kliewer EV et al (2008) Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 123:2390–2396
23. Rennemo E, Zätterström U, Boysen M (2008) Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope 118:1350–1356
24. Tiwana MP, Hay J, Wu J, Wong F, Cheung W, Olson RA (2014) Incidence of second metachronous head and neck cancers: population-based outcomes over 25 years. Laryngoscope 124:2287–2291
25. Wolff HA, Wolff CRM, Hess CF, Jung K, Sennhenn-Kirchner S, Hinterthainer M et al (2013) Second primary malignancies in head and neck cancer patients: high prevalence of curable-stage disease. Strahlenther Onkol 189:874–880
26. Bugter O, van Iwaarden DLP, van Leeuwen N, Nieboer D, Dronkers EAC, Hardillo JAU et al (2021) A cause-specific Cox model for second primary tumors in patients with head and neck cancer: a RONCDOC study. Head Neck 43:1881–1889
27. Boakye EA, Buchanan P, Hinyard L, Osazuwa-Peters N, Simpson MC, Schootman M et al (2019) Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. Int J Cancer 145:143–153
28. Arie GB, Shafat T, Belochitski O, El-Saied S, Joshua BZ (2021) Treatment modality and second primary tumors of the head and neck. Otol J Otorhinolaryngol Relat Spec 83:420–427
29. Arie Boakye E, Buchanan P, Hinyard L, Osazuwa-Peters N, Schootman M, Piccirillo JF (2018) Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 144:727–738
30. Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P et al (2017) Double-blind, randomized phase III trial of low-dose 13-cisretinoic acid in prevention of second primaries in head and neck cancer: long-term follow-up of a trial of the ECOG-ACRIN cancer research group (C0590). Cancer 123:4653–4662
31. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P et al (1994) Synchronous and metachronous head and neck carcinomas. Cancer 74:1933–1938
32. Adeel M, Siddiqui MI (2018) Metachronous second primary malignancy in head and neck cancer patients: Is five years of follow-up sufficient? J Korean Assoc Oral Maxillofac Surg 44:220–224